Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
AssigneePharmacia Corporation
InventorsDiane T. Stephenson, Duncan P. Taylor
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for the treatment of a vaso-occlusive event. More particularly, the invention provides a combination therapy for the treatment of a vaso-occlusive event comprising the administration to a subject of a selective serotonin reuptake inhibitor in combination with a cyclooxygenase-2 selective inhibitor.
Claims57
A method of treating a vaso-occlusive event, the method comprising:
- (a) diagnosing a subject in need of treatment for a vaso-occlusive event;
- and
- (b) administering to the subject a combination comprising a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof 5 and a selective serotonin reuptake inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof.
A method of treating a vaso-occlusive event, the method comprising:
- (a) diagnosing a subject in need of treatment for a vaso-occlusive event;
- and
- (b) administering to the subject a combination comprising a selective serotonin reuptake inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the cyclooxygenase-2 selective inhibitor is a chromene compound, the chromene compound comprising a benzothiopyran, a dihydroquinoline or a dihydronaphthalene.
A method of treating a vaso-occlusive event, the method comprising:
- (a) diagnosing a subject in need of treatment for a vaso-occlusive event;
- and
- (b) administering to the subject a combination comprising a selective serotonin reuptake inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the cyclooxygenase-2 selective inhibitor is a tricyclic compound, the tricyclic compound comprising a benzenesulfonamide or methylsulfonylbenzene.
A method of treating a vaso-occlusive event, the method comprising:
- (a) diagnosing a subject in need of treatment for a vaso-occlusive event;
- and
- (b) administering to the subject a combination comprising a selective serotonin reuptake inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the cyclooxygenase-2 selective inhibitor is a phenyl acetic acid compound.
38 The method of claim 37 wherein the cyclooxgenase-2 selective inhibitor has a selectivity ratio of COX-1 IC50 to COX-2 IC50 not less than about 50.
A method of treating a vaso-occlusive event, the method comprising:
- (a) diagnosing a subject in need of treatment for a vaso-occlusive event;
- and
- (b) administering to the subject a combination comprising a cyclooxygenase-2 selective inhibitor selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, lumiracoxib, etoricoxib, parecoxib, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid;
- and
- a selective serotonin reuptake inhibitor selected from the group consisting of citalopram, fluoxetine, fluvoxamine, paroxetine, escitalopram oxalate, sertraline, norfluoxetine and N-demethylsertraline.
56 The method of claim 47 wherein the cyclooxygenase-2 selective inhibitor is lumiracoxib.
Dependencies are inferred from the claim text.